{"gene":"MAPK1","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1998,"finding":"Phosphorylated ERK2 forms homodimers with both phosphorylated and unphosphorylated ERK2 partners; disruption of dimerization by mutagenesis reduces nuclear accumulation, establishing that dimerization is required for ligand-dependent nuclear translocation. Crystal structure of phosphorylated ERK2 reveals the structural basis for dimerization.","method":"Microinjection of ERK2 into cells, site-directed mutagenesis, crystal structure of phospho-ERK2","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with mutagenesis and functional nuclear-localization assay in a single rigorous study","pmids":["9604935"],"is_preprint":false},{"year":1999,"finding":"Residues 312–320 of ERK2 constitute a cytoplasmic-retention sequence that mediates association with MEK1, keeping ERK2 in the cytosol in resting cells; residues 321–327 are required for nuclear translocation upon mitogenic stimulation. Key acidic residues at positions 316, 319, and 320 are essential for cytosolic retention.","method":"GFP-ERK2 fusion constructs expressed in CHO cells, alanine-scanning mutagenesis, co-expression with MEK1, fluorescence microscopy","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of specific residues with direct functional readout (cytosolic vs. nuclear localization), single lab but multiple mutant constructs and orthogonal approaches","pmids":["10521408"],"is_preprint":false},{"year":2002,"finding":"ERK2 enters the nucleus by a carrier- and energy-independent mechanism involving direct binding to nucleoporins of the nuclear pore complex, competing with canonical transport factors for pore access.","method":"In vitro nuclear import assay with GFP-ERK2, wheat germ agglutinin inhibition, recombinant transport factor competition, direct binding to purified nucleoporin","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro import assay with multiple orthogonal inhibition approaches and direct nucleoporin binding experiment","pmids":["12032311"],"is_preprint":false},{"year":2000,"finding":"ERK2 catalytic mechanism proceeds via rapid-equilibrium ATP binding followed by diffusion-limited MBP binding and rate-limiting phosphoryl transfer (kcat ~10 s⁻¹), with product release faster than phosphoryl transfer.","method":"Steady-state kinetics and solvent viscosimetry with purified ERK2, MBP, and ERKtide peptide substrates","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstituted kinetic analysis with viscosimetric probes; single lab but multiple substrates and rigorous mechanistic dissection","pmids":["10821702"],"is_preprint":false},{"year":2006,"finding":"Crystal structure of ERK2 bound to the KIM peptide of MAP kinase phosphatase 3 (MKP3) reveals that the docking site on ERK2 comprises a highly acidic patch and a hydrophobic groove that engage the basic and hydrophobic residues of the KIM sequence; this docking site is distinct from the catalytic pocket.","method":"X-ray crystallography of ERK2:KIM peptide complex","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with validation against existing biochemical data; replicated mechanistic insight across multiple MAPK family members","pmids":["16567630"],"is_preprint":false},{"year":2014,"finding":"Dual phosphorylation of ERK2 by MEK1 releases conformational constraints at the hinge between N- and C-terminal domains, inducing global two-state conformational exchange (kex ~300 s⁻¹) throughout the kinase core including the catalytic pocket, thereby promoting catalytic activity.","method":"NMR ¹³C relaxation dispersion (Ile/Leu/Val methyl side chains), hinge-mutant ERK2 engineering","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR with mutagenesis validation, single lab but multiple ERK2 states and engineered mutant corroboration","pmids":["24550275"],"is_preprint":false},{"year":2019,"finding":"ERK inhibitors Vertex-11e and SCH772984 exploit two distinct conformational states (L and R) of active 2P-ERK2: Vertex-11e stabilizes the R (domain-closed, catalytically competent) state while a SCH772984 analog blocks domain closure; these conformational differences differentially regulate MAP kinase phosphatase-mediated dephosphorylation of ERK2.","method":"X-ray crystallography of 2P-ERK2 complexes, NMR hydrogen-exchange MS (HX-MS), kinase conformation analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple crystal structures plus HX-MS, mechanistic validation of opposing conformational effects on phosphatase activity","pmids":["31311868"],"is_preprint":false},{"year":2004,"finding":"IQGAP1 directly binds ERK2 in vitro and co-immunoprecipitates with endogenous ERK2 from human breast epithelial cells; manipulation of IQGAP1 levels modulates growth-factor-stimulated ERK1/2 activity, and an IQGAP1 construct lacking the ERK2-binding region fails to interfere with ERK activation.","method":"In vitro pull-down with purified proteins, co-immunoprecipitation from cell lysates, overexpression/knockdown of IQGAP1, kinase activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus in vitro direct-binding assay plus functional kinase activity readout; single lab, multiple orthogonal methods","pmids":["14970219"],"is_preprint":false},{"year":2000,"finding":"Endogenous MEKK1 binds endogenous ERK2, MEK1, and Raf-1, indicating that MEKK1 can serve as a scaffold assembling all three kinases of the ERK MAP kinase module.","method":"Co-immunoprecipitation of endogenous proteins from cell lysates","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — endogenous Co-IP supporting scaffold function; single lab, single method","pmids":["10969079"],"is_preprint":false},{"year":2003,"finding":"Using an engineered ERK2 (Q103G) that accepts a bulky ATP analog, EDD (ubiquitin E3 ligase) and nucleoporin Tpr were identified as novel direct ERK2 substrates; EDD phosphorylation by ERK2 was confirmed both in vitro and in vivo.","method":"Chemical genetics (engineered kinase + ATP analog), phosphorylation of ERK2-associated proteins in COS-1 cells, in vitro kinase assay, in vivo phosphorylation validation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — chemical-genetic substrate ID method with in vitro and in vivo validation; single lab with two orthogonal confirmation approaches","pmids":["12594221"],"is_preprint":false},{"year":1999,"finding":"Phosphorylated (active) ERK2 directly associates with GAB1 via its MET-binding domain without requiring a third protein; ERK2 phosphorylates GAB1 in vitro and in cells, with new phosphorylation sites appearing upon MEK1 co-transfection.","method":"GST pull-down with bacterially expressed proteins, co-immunoprecipitation in A293 cells, in vitro kinase assay, phosphopeptide mapping","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vitro binding confirmed with purified proteins, plus cellular Co-IP and in vivo phosphorylation; single lab","pmids":["10593929"],"is_preprint":false},{"year":2004,"finding":"Adhesion stimulates a direct physical interaction between PAK1 and ERK2; ERK2 phosphorylates PAK1 at Thr212 in vitro and in PDGF-treated smooth muscle cells in an adhesion- and MEK/ERK-dependent manner; a phosphomimic PAK1-T212E attenuates downstream ERK signaling, suggesting a negative feedback loop.","method":"Co-immunoprecipitation, far-Western analysis, peptide mapping of ERK2 binding site, in vitro kinase assay, SRE-luciferase reporter, immunofluorescence co-localization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro binding and phosphorylation confirmed with in vivo validation; single lab with multiple orthogonal methods","pmids":["15542607"],"is_preprint":false},{"year":2005,"finding":"ERK2 mediates proximity-induced (docking-dependent) catalysis: the pnt domain of substrate EtsDelta138 docks outside the active site, increasing effective concentration of the phosphorylatable TP motif near the catalytic pocket; disruption of the pnt-domain interaction (F120A) reduces binding 10-fold without affecting kcat, while mutagenesis of the TP motif decreases kcat without affecting docking.","method":"In vitro kinase assays with ERK2 and domain/point mutants of EtsDelta138, equilibrium binding measurements","journal":"Journal of the American Chemical Society","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with systematic mutagenesis of both enzyme substrate-recognition domain and substrate docking motif; single lab, multiple mutants","pmids":["16045329"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of the ERK2–RSK1 heterodimeric complex captures a precatalytic state where the RSK1 activation loop faces the ERK2 catalytic site; the MAPK-binding linear motif of RSK1 interacting with the ERK2 docking groove is the primary determinant of complex formation, and domain contacts between the kinase cores shift the complex into a catalytically competent state.","method":"X-ray crystallography, molecular dynamics simulation, biochemical assays, cellular signaling studies","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with MD simulation and biochemical/cellular validation; multiple orthogonal methods","pmids":["25730857"],"is_preprint":false},{"year":2011,"finding":"SAXS analysis shows the resting-state ERK2:HePTP complex is extended and dynamic, whereas the active-state complex is compact and ordered, demonstrating that these regulatory complexes undergo significant dynamic structural rearrangement in solution.","method":"Small-angle X-ray scattering (SAXS) with EROS ensemble refinement","journal":"Journal of the American Chemical Society","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — structural method (SAXS) on purified complexes; single lab, no orthogonal functional validation","pmids":["21985012"],"is_preprint":false},{"year":2006,"finding":"ERK2 (but not ERK1, JNK1, JNK2, p38α, or p38β) is required for cytosolic lipid droplet formation; ERK2 acts downstream of PLD1, and ERK2 increases phosphorylation of dynein, which increases dynein association with ADRP-containing lipid droplets; antibody inhibition of dynein strongly blocks lipid droplet formation.","method":"Overexpression, siRNA knockdown, microinjection of ERK2 and PLD1, pharmacological inhibition, dynein phosphorylation assay, antibody microinjection","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal manipulations (OE, KD, microinjection) with pathway ordering; single lab","pmids":["16723731"],"is_preprint":false},{"year":2013,"finding":"ERK2 directly interacts with Par3 and phosphorylates it at Ser-1116; phosphorylated Par3 accumulates at axonal tips but its interaction with KIF3A is inhibited, slowing axonal transport and impairing neuronal polarization in cultured hippocampal neurons and mouse cortical neurons in vivo.","method":"Co-immunoprecipitation, in vitro kinase assay, phosphomimic/phospho-null mutants, RNAi rescue experiments in cultured neurons and in vivo cortical neurons","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct binding, in vitro phosphorylation, phosphomimic rescue, and in vivo validation; multiple orthogonal methods","pmids":["23946386"],"is_preprint":false},{"year":2020,"finding":"ERK2 (but not ERK1) phosphorylates PFAS (phosphoribosylformylglycinamidine synthase) at Thr619 to stimulate de novo purine synthesis flux; non-phosphorylatable PFAS-T619A decreases purine synthesis and reduces RAS-dependent cancer cell colony formation and tumor growth.","method":"In vitro kinase assay with purified ERK2, ¹³C metabolic flux analysis, phosphomutant expression, colony formation and xenograft tumor assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus metabolic flux measurement plus phosphomutant functional studies in cells and in vivo; single lab with multiple orthogonal approaches","pmids":["32485148"],"is_preprint":false},{"year":2020,"finding":"MAPK1/ERK2 phosphorylates ULK1, triggering its interaction with the E3 ligase BTRC and subsequent K48-linked ubiquitination and proteasomal degradation, thereby attenuating mitophagy and promoting NLRP3 inflammasome activation and breast cancer bone metastasis.","method":"Co-immunoprecipitation, in vitro ubiquitination assay, MEK inhibitor (trametinib) rescue, xenograft mouse model, human breast cancer tissue correlation","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical pathway dissection with Co-IP, pharmacological rescue, and in vivo validation; single lab","pmids":["33213267"],"is_preprint":false},{"year":2017,"finding":"ERK2, together with Akt and IKK1/2, phosphorylates Bcl3 at Ser114 and Ser446; ERK2/IKK1/2-mediated phosphorylation converts Bcl3 from an IκB-like inhibitor into a transcriptional co-regulator by facilitating its recruitment to DNA; cells expressing S114A/S446A Bcl3 show proliferation and migration defects.","method":"In vitro kinase assays, phosphomutant expression, co-immunoprecipitation, DNA-binding assays, cellular proliferation/migration assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus phosphomutant functional studies with defined cellular readouts; single lab with multiple orthogonal methods","pmids":["28689659"],"is_preprint":false},{"year":2016,"finding":"ERK2 and Cdk1 hyperphosphorylate CPEB4 in M-phase to maintain it as a monomer and activate its mRNA-translation regulatory function; unphosphorylated CPEB4 phase-separates into inactive liquid-like droplets through its intrinsically disordered N-terminal domain.","method":"In vitro phosphorylation assays, phosphomutant analysis, phase-separation assays, cell cycle synchronization, fluorescence microscopy","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase and phase-separation assays with cell-cycle validation; single lab","pmids":["27802129"],"is_preprint":false},{"year":2019,"finding":"ERK2 (but not ERK1) binds Shank3 and phosphorylates it at three residues to promote poly-ubiquitination-dependent proteasomal degradation of Shank3; genetic deletion or pharmacological inhibition of ERK2 increases Shank3 abundance in vivo.","method":"Kinome-wide siRNA screen, co-immunoprecipitation, in vitro kinase assay, ERK2 knockout mice, pharmacological inhibition","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 2 / Strong — screen followed by direct biochemical validation (Co-IP, in vitro phosphorylation), in vivo knockout confirmation; multiple orthogonal methods","pmids":["30696942"],"is_preprint":false},{"year":2019,"finding":"ERK2 induces EMT by upregulating Dock10 (a Rac1/Cdc42 GEF), which activates Rac1/JNK signaling, leading to increased FoxO1 expression; ERK2-dependent FoxO1 regulation promotes epithelial-to-mesenchymal plasticity.","method":"Global gene expression analysis (ERK2-specific), co-immunoprecipitation, RNAi, reporter assays, cell migration assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established by gene expression profiling followed by functional RNAi rescue; single lab","pmids":["30728292"],"is_preprint":false},{"year":2015,"finding":"Under sustained metabolic (low-glucose) stress, MEK1/ERK2 isoform-specific signaling induces GCN2/eIF2α phosphorylation and ATF4 expression, which overrides PERK/Akt-mediated survival and induces apoptosis through ATF4-dependent pro-apoptotic factors (Bid, Trb3); ERK2 activation also alters TCA cycle and amino acid metabolism.","method":"Isoform-specific knockdown/overexpression, phosphoprotein analysis, metabolomics (TCA cycle, amino acid profiling), apoptosis assays","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-selective KD with metabolic and signaling readouts; single lab, multiple orthogonal measurements","pmids":["26190261"],"is_preprint":false},{"year":2008,"finding":"Mitochondrial localization of active ERK2 (but not kinase-dead ERK2) is sufficient to induce mitophagy and autophagic cell death; constitutively active ERK2 localizes more strongly to mitochondria than WT ERK2, and these mitochondria-associated ERK2 granules undergo autophagic degradation.","method":"GFP-ERK2 fusion constructs (WT, CA, KD), live-cell fluorescence microscopy, co-localization with mitochondrial and autophagolysosomal markers, bafilomycin-A inhibitor experiments, LC3 autophagy marker analysis","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization imaging with kinase-dead vs. active mutant comparison and pharmacological validation; single lab","pmids":["18594198"],"is_preprint":false},{"year":2017,"finding":"ERK2 kinase activity drives a specific phenotype switch (transcriptional reprogramming resembling EMT, including shutdown of MITF) that underlies drug addiction in BRAF-inhibitor-resistant melanoma cells; disruption of an ERK2-JUNB-FRA1 signaling pathway allows addicted cells to survive drug withdrawal.","method":"Unbiased CRISPR-Cas9 knockout screen, ERK2-specific rescue experiments, in vitro and in vivo (mouse) models, patient tissue analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — unbiased genome-wide screen validated by rescue experiments in cells and mice; replicated across multiple resistance mechanisms","pmids":["28976960"],"is_preprint":false},{"year":2014,"finding":"PLAC8 directly binds and inactivates the ERK2 phosphatase DUSP6 in vitro, thereby increasing phospho-ERK2 levels; ERK2 knockdown reverses PLAC8-induced EMT features (restored CDH1, suppressed CDH3/VIM/ZEB1), placing ERK2 downstream of PLAC8-DUSP6 in an unconventional EMT pathway in colon cancer.","method":"In vitro DUSP6 activity assay with recombinant PLAC8, ERK2 knockdown, xenograft tumor model, MultiOmyx multiplex immunofluorescence","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vitro phosphatase inhibition assay plus ERK2 KD epistasis plus in vivo validation; single lab","pmids":["24691442"],"is_preprint":false},{"year":2009,"finding":"Nesprin-2 acts as a nuclear scaffold that tethers active ERK1/2 at PML nuclear bodies; knockdown or dominant-negative disruption of nesprin-2 augments ERK1/2 nuclear signaling (increased SP1 activity and ELK1 phosphorylation) and increases cell proliferation; this function is mediated by nuclear nesprin-2 isoforms lacking the KASH domain.","method":"Immunofluorescence co-localization, GST pull-down, co-immunoprecipitation, siRNA knockdown, dominant-negative overexpression, reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and pull-down with functional readouts; single lab, multiple complementary approaches","pmids":["19861416"],"is_preprint":false},{"year":2016,"finding":"PARP1 binds phosphorylated ERK2 in neuronal chromatin upon stimulation; ERK2-induced PARP1 activation renders immediate early gene (IEG) promoters accessible to phospho-ERK2, mediating IEG expression required for LTP; PARP1 inhibition or deletion abrogates ERK2 recruitment to IEG promoters and prevents LTP generation.","method":"Co-immunoprecipitation of chromatin-bound proteins, PARP1 inhibition/knockdown/knockout, ERK2 chromatin-immunoprecipitation, LTP electrophysiology in hippocampal slices","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating ERK2 recruitment to IEG promoters with PARP1 dependency; multiple loss-of-function approaches; single lab","pmids":["27121568"],"is_preprint":false},{"year":2004,"finding":"Noonan syndrome PTPN11 (SHP2) gain-of-function mutants cause prolonged ERK2/MAPK1 activation in a ligand (EGF)-dependent, GAB1-docking-dependent manner; co-expression of GAB1-FF (lacking SHP2-binding motifs) dramatically reduces ERK2 activation, establishing the SHP2→GAB1→ERK2 pathway axis.","method":"Phosphatase activity assays, ERK2 kinase assays, co-immunoprecipitation of SHP2 with GAB1, dominant-negative GAB1 epistasis, cell proliferation assays","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical pathway epistasis with multiple mutants and direct kinase/phosphatase assays; single lab","pmids":["14974085"],"is_preprint":false},{"year":2020,"finding":"In Xenopus embryos, mechanical forces (centrifugal, compression, stretching) activate ERK2 via FGFR1 independently of FGF ligands; ERK2 activation remodels cytoskeletal proteins (F-actin, C-cadherin, ZO-1) to enhance cellular junctions and tissue stiffening.","method":"Xenopus embryo mechanical stimulation, phosphoproteome analysis, FGFR1 inhibition, fluorescence imaging of cytoskeletal markers","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomics-guided functional analysis with pharmacological epistasis in a developmental model; single lab","pmids":["32187556"],"is_preprint":false},{"year":2012,"finding":"ERK2 (but not ERK1) silencing inhibits invasive migration in 3D matrices; ERK2 re-expression (not ERK1) restores invasion; ERK2 suppresses expression of Rab17 and liprin-β2, which inhibit invasion; knockdown of either Rab17 or liprin-β2 restores invasiveness of ERK2-depleted cells.","method":"siRNA knockdown, isoform-specific rescue, 3D matrix migration assays, gene expression arrays, secondary knockdown epistasis","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-selective rescue with downstream gene epistasis; single lab, multiple cancer cell lines","pmids":["22328529"],"is_preprint":false},{"year":2013,"finding":"ERK2 directly interacts with and phosphorylates Par3 at Ser-1116, inhibiting Par3–KIF3A interaction; phosphomimic Par3-S1116D shows reduced KIF3A binding and slower axonal transport, impairing neuronal polarization in hippocampal neurons and cortical projection neurons in vivo.","method":"Co-immunoprecipitation, in vitro kinase assay, phosphomimic/phospho-null mutants expressed in cultured neurons and in vivo mouse cortex via in utero electroporation, RNAi rescue","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro phosphorylation with site identification, phosphomutant functional rescue in cultured neurons and in vivo; multiple orthogonal methods, replicated in two neuronal systems","pmids":["23946386"],"is_preprint":false},{"year":2005,"finding":"PEA-15 sequesters ERK2 in the cytoplasm by competing with DEJL-domain-containing substrates/activators for binding to ERK2; the C-terminus of PEA-15 (residues 121–129) constitutes a reverse DEJL domain mediating one arm of a bidentate interaction with ERK2.","method":"Fluorescence anisotropy binding assays with purified ERK2 and PEA-15/peptides, competition experiments with DEJL-derived peptides","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — quantitative in vitro binding assay with mechanistic model; single lab, single method","pmids":["16324895"],"is_preprint":false},{"year":2024,"finding":"High glucose conditions increase MAPK1 activity, which lowers PACS-2 (a MAM tethering protein) levels, causing mitochondria-associated ER membrane (MAM) disruption and mitochondrial fragmentation in renal tubular cells; inhibition of MAPK1 restores PACS-2 and protects against MAM loss and mitochondrial fragmentation in diabetic mice.","method":"Diabetic mouse and human kidney tissue analysis, HK-2 cell high-glucose model, MAPK1 inhibition (pharmacological), PACS-2 rescue overexpression","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function pharmacological approach with PACS-2 rescue in cells and in vivo; single lab, multiple models","pmids":["38169625"],"is_preprint":false},{"year":2016,"finding":"MAPK1/ERK2 activation ameliorates hepatic steatosis through ATG7-dependent autophagy; knockdown of MAPK1/3 promotes liver steatosis, reduces autophagic flux and ATG7 levels in primary hepatocytes; blockade of autophagy (chloroquine or ATG7 knockdown) reverses the anti-steatosis effect of MAPK1/3 activation.","method":"Adenoviral MAPK1/3 activation in db/db mice, siRNA knockdown, autophagic flux assays, ATG7 expression analysis, pharmacological autophagy blockade","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function and loss-of-function with epistasis through ATG7 knockdown; single lab, in vitro and in vivo","pmids":["26760678"],"is_preprint":false},{"year":2020,"finding":"MAPK1 binds to promoter regions of target genes in gastric cancer cells and functions as a bidirectional transcription factor (independent of its kinase role), upregulating KRT13, KRT6A, KRT81, MYH15, STARD4, SYTL4, TMEM267 and downregulating FGG, thereby promoting cell motility and invasion.","method":"ChIP-seq, RNA-seq, ChIP assays, chromatin immunoprecipitation confirming MAPK1 at promoters, cell proliferation and migration assays","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq and ChIP with functional readouts; single lab, single cell line","pmids":["37817112"],"is_preprint":false}],"current_model":"ERK2/MAPK1 is a dual-specificity-regulated serine/threonine kinase that is activated by MEK1/2-mediated dual phosphorylation on TEY residues, triggering global conformational changes that enhance catalytic activity; phospho-ERK2 homodimerizes and translocates to the nucleus by binding directly to nuclear pore complex nucleoporins (carrier-independent), while in resting cells it is held in the cytoplasm via a C-terminal retention sequence that mediates MEK1 association; in the nucleus it phosphorylates substrates (e.g., ELK-1, PARP1-associated IEG promoters, Par3, CPEB4) docked through a conserved acidic-patch/hydrophobic-groove KIM-docking site, and in the cytoplasm it phosphorylates diverse substrates including PFAS (stimulating de novo purine synthesis), ULK1 (triggering its ubiquitin-dependent degradation and limiting mitophagy), PAK1 (negative feedback), Shank3 (promoting degradation), and Par3 (regulating axon polarity); its activity is spatially organized by scaffold proteins such as IQGAP1, nesprin-2 (at PML nuclear bodies), and MEKK1, and is negatively regulated by phosphatases (MKP3/DUSP6) that engage the same KIM docking groove, with conformational selection by small-molecule inhibitors further modulating dephosphorylation susceptibility."},"narrative":{"mechanistic_narrative":"MAPK1/ERK2 is a serine/threonine kinase that serves as a terminal effector of the ERK MAP kinase module, converting mitogenic and mechanical inputs into transcriptional, metabolic, and cytoskeletal outputs [PMID:10969079, PMID:32187556]. Activation is governed by MEK1-mediated dual phosphorylation, which releases conformational constraints at the hinge between the N- and C-terminal lobes to drive global two-state conformational exchange throughout the catalytic core and promote activity [PMID:24550275], with catalysis proceeding through rapid-equilibrium ATP binding followed by rate-limiting phosphoryl transfer [PMID:10821702]. Substrate and regulator engagement is directed by a docking site distinct from the catalytic pocket—an acidic patch and hydrophobic groove that bind KIM/linear motifs of partners such as the phosphatase MKP3 and the kinase RSK1, the latter captured in a precatalytic heterodimeric state [PMID:16567630, PMID:25730857]; proximity-based docking increases the effective concentration of phosphoacceptor motifs near the active site [PMID:16045329]. Subcellular targeting is tightly controlled: a C-terminal retention sequence (residues 312–320) holds ERK2 in the cytosol via MEK1 association in resting cells, while activation promotes homodimerization and carrier-independent nuclear entry through direct nucleoporin binding [PMID:9604935, PMID:10521408, PMID:12032311]. ERK2 phosphorylates a broad substrate repertoire to control diverse processes—PFAS to stimulate de novo purine synthesis [PMID:32485148], ULK1 to trigger its ubiquitin-dependent degradation and restrain mitophagy [PMID:33213267], Par3 to regulate axonal transport and neuronal polarity [PMID:23946386], CPEB4 to control its phase behavior and mRNA-translation activity [PMID:27802129], Shank3 and PAK1 to drive their degradation or feedback inhibition [PMID:30696942, PMID:15542607], and transcriptional regulators including Bcl3 and the IEG machinery via PARP1 [PMID:28689659, PMID:27121568]. ERK2 activity is spatially organized by scaffolds and tethers including IQGAP1, MEKK1, and nesprin-2 at PML nuclear bodies [PMID:14970219, PMID:10969079, PMID:19861416], and counter-regulated by phosphatases whose dephosphorylation efficiency depends on ERK2 conformational state [PMID:31311868, PMID:24691442]. ERK2-specific signaling drives epithelial-mesenchymal plasticity, invasion, and BRAF-inhibitor-resistant melanoma phenotypes, frequently distinguishing it functionally from ERK1 [PMID:28976960, PMID:22328529, PMID:30728292].","teleology":[{"year":1998,"claim":"Established how active ERK2 reaches the nucleus, resolving whether nuclear accumulation required oligomerization—dimerization of phospho-ERK2 was shown to be necessary for ligand-dependent nuclear translocation.","evidence":"Microinjection, site-directed mutagenesis, and crystal structure of phospho-ERK2","pmids":["9604935"],"confidence":"High","gaps":["Did not identify the nuclear import machinery used","Dimerization-independent functions not addressed"]},{"year":1999,"claim":"Defined the molecular basis for cytoplasmic retention versus nuclear targeting, mapping a C-terminal retention sequence that anchors ERK2 to MEK1 in resting cells and a separate segment required for translocation.","evidence":"GFP-ERK2 fusions in CHO cells with alanine-scanning mutagenesis and MEK1 co-expression","pmids":["10521408"],"confidence":"High","gaps":["How activation overrides retention not mechanistically resolved","Did not address the translocation machinery"]},{"year":2000,"claim":"Addressed how ERK2 catalysis is timed and how the kinase module assembles—kinetic dissection set phosphoryl transfer as rate-limiting, and MEKK1 was shown to bind ERK2, MEK1, and Raf-1 as a candidate scaffold.","evidence":"Steady-state kinetics with viscosimetry on purified ERK2; endogenous co-immunoprecipitation","pmids":["10821702","10969079"],"confidence":"High","gaps":["MEKK1 scaffold stoichiometry and cellular requirement not established","Kinetics on physiological substrates beyond MBP/peptide limited"]},{"year":2002,"claim":"Determined the mechanism of ERK2 nuclear import, showing it occurs by carrier- and energy-independent direct binding to nucleoporins rather than canonical import factors.","evidence":"Reconstituted in vitro import assay with WGA inhibition, transport-factor competition, and direct nucleoporin binding","pmids":["12032311"],"confidence":"High","gaps":["Reconciliation with dimerization requirement for import not fully integrated","Which nucleoporins are physiologically rate-limiting unclear"]},{"year":2006,"claim":"Resolved the structural basis of substrate/regulator selection, showing a docking site (acidic patch plus hydrophobic groove) distinct from the catalytic pocket engages KIM motifs.","evidence":"X-ray crystallography of ERK2:MKP3 KIM peptide complex","pmids":["16567630"],"confidence":"High","gaps":["Does not capture full-length phosphatase or substrate complex dynamics","Selectivity determinants among different KIM motifs not exhaustively defined"]},{"year":2005,"claim":"Clarified how docking translates into catalytic efficiency, demonstrating proximity-induced catalysis where substrate domains dock outside the active site to raise effective concentration of the phosphoacceptor motif.","evidence":"In vitro kinase assays with domain/point mutants of EtsDelta138 and binding measurements","pmids":["16045329"],"confidence":"High","gaps":["Generality across all substrate classes not tested","In vitro reconstitution only"]},{"year":2014,"claim":"Explained how phosphorylation activates the kinase at the conformational level, showing TEY phosphorylation releases hinge constraints to drive global two-state exchange that reaches the catalytic pocket.","evidence":"NMR 13C relaxation dispersion with hinge-mutant ERK2 engineering","pmids":["24550275"],"confidence":"High","gaps":["Direct link between specific conformer and substrate turnover rates not fully quantified"]},{"year":2019,"claim":"Connected ERK2 conformational state to drug action and regulation, showing inhibitors stabilizing distinct L/R states differentially affect phosphatase-mediated dephosphorylation.","evidence":"X-ray crystallography and HX-MS of 2P-ERK2 inhibitor complexes","pmids":["31311868"],"confidence":"High","gaps":["In-cell consequences of conformation-selective dephosphorylation not measured","Effect on individual substrate selection unclear"]},{"year":2004,"claim":"Identified ERK2 scaffolds and feedback substrates, establishing IQGAP1 as a direct binding partner modulating ERK1/2 activity and PAK1 as an adhesion-dependent substrate forming a negative feedback loop.","evidence":"In vitro pull-down, reciprocal Co-IP, knockdown/overexpression, far-Western, in vitro kinase and reporter assays","pmids":["14970219","15542607"],"confidence":"High","gaps":["Quantitative contribution of IQGAP1 scaffolding to physiological ERK output unclear","PAK1 feedback magnitude in vivo not defined"]},{"year":2003,"claim":"Expanded the ERK2 substrate landscape using chemical genetics, identifying the E3 ligase EDD and the nucleoporin Tpr as direct substrates.","evidence":"Engineered ERK2(Q103G) with bulky ATP analog, in vitro and in vivo phosphorylation validation","pmids":["12594221"],"confidence":"High","gaps":["Functional consequences of EDD/Tpr phosphorylation not defined"]},{"year":2015,"claim":"Linked ERK2 to upstream activating receptors and to a downstream kinase, defining the SHP2→GAB1→ERK2 axis and capturing the ERK2–RSK1 precatalytic complex.","evidence":"Crystallography with MD simulation (RSK1); phosphatase/kinase assays and dominant-negative GAB1 epistasis (SHP2/GAB1)","pmids":["25730857","10593929","14974085"],"confidence":"High","gaps":["Dynamics of transition to fully catalytic RSK1 complex inferred from structure","GAB1 axis studied largely via overexpression/mutants"]},{"year":2011,"claim":"Demonstrated that ERK2 regulatory complexes are conformationally dynamic, with resting ERK2:HePTP extended and the active complex compact in solution.","evidence":"SAXS with EROS ensemble refinement on purified complexes","pmids":["21985012"],"confidence":"Medium","gaps":["No orthogonal functional validation","Single structural method"]},{"year":2016,"claim":"Defined ERK2 control of regulated proteins via degradation and phase behavior, and its role in chromatin-based gene activation, showing ULK1/Shank3 degradation, CPEB4 monomerization, and PARP1-dependent recruitment to IEG promoters.","evidence":"In vitro kinase/ubiquitination and phase-separation assays, Co-IP, ChIP, knockout mice, LTP electrophysiology","pmids":["27802129","27121568","30696942","33213267"],"confidence":"Medium","gaps":["Several pathways rest on single-lab Co-IP plus rescue","Direct vs. indirect contributions in vivo not fully separated"]},{"year":2020,"claim":"Established ERK2 as a metabolic and organelle regulator, phosphorylating PFAS to boost de novo purine synthesis and modulating mitochondrial dynamics through PACS-2/MAM control.","evidence":"In vitro kinase assay, 13C metabolic flux analysis, phosphomutant xenografts; diabetic mouse/HK-2 models with MAPK1 inhibition and PACS-2 rescue","pmids":["32485148","38169625"],"confidence":"High","gaps":["PACS-2 regulation mechanism (direct vs. indirect) not fully defined","ERK1 vs. ERK2 specificity for PACS-2 effect untested"]},{"year":2020,"claim":"Revealed kinase-independent and isoform-specific ERK2 functions, including bidirectional transcription-factor activity at gastric cancer promoters and mechanically activated ERK2 remodeling cytoskeletal junctions.","evidence":"ChIP-seq/RNA-seq with functional assays; Xenopus mechanical stimulation with phosphoproteomics and FGFR1 inhibition","pmids":["37817112","32187556"],"confidence":"Medium","gaps":["Kinase-independent transcriptional role shown in a single cell line","Direct DNA-binding mechanism not structurally defined"]},{"year":2017,"claim":"Connected ERK2-specific activity to disease-relevant phenotypes, showing ERK2 drives EMT, invasion, and BRAF-inhibitor-resistant melanoma drug addiction distinct from ERK1.","evidence":"CRISPR knockout screens, isoform-specific rescue, 3D invasion assays, mouse models, patient tissue analysis","pmids":["28976960","22328529","30728292","24691442","28689659"],"confidence":"High","gaps":["Molecular basis of ERK2 vs ERK1 functional divergence incompletely defined","Some downstream pathways established by epistasis rather than direct substrate phosphorylation"]},{"year":null,"claim":"How ERK2 achieves substrate-specific outputs from a single conformationally dynamic active site—integrating docking, scaffolding, localization, and kinase-independent functions—remains incompletely defined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking conformational state to substrate selection in cells","Kinase-independent transcription-factor role mechanistically unresolved","Determinants of ERK1 vs ERK2 isoform specificity unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,11,12,16,17,19,20,21,32]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[3,9,17]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[3]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[36]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[36,28]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,33]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,2,27]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[2]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[24,34]},{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[15]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[28]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,29,30]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[18,24,35]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[17,23,34]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[19,28,36]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[25,26,29]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[16,30,32]}],"complexes":[],"partners":["MEK1","MKP3/DUSP6","RSK1","IQGAP1","MEKK1","GAB1","PAK1","PAR3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P28482","full_name":"Mitogen-activated protein kinase 1","aliases":["ERT1","Extracellular signal-regulated kinase 2","ERK-2","MAP kinase isoform p42","p42-MAPK","Mitogen-activated protein kinase 2","MAP kinase 2","MAPK 2"],"length_aa":360,"mass_kda":41.4,"function":"Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade also plays a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1 and FXR1) and a variety of other signaling-related molecules (like ARHGEF2, DCC, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade. Mediates phosphorylation of TPR in response to EGF stimulation. May play a role in the spindle assembly checkpoint. Phosphorylates PML and promotes its interaction with PIN1, leading to PML degradation. Phosphorylates CDK2AP2 (By similarity). Phosphorylates phosphoglycerate kinase PGK1 under hypoxic conditions to promote its targeting to the mitochondrion and suppress the formation of acetyl-coenzyme A from pyruvate (PubMed:26942675). Phosphorylates GJA1 at 'Ser-279' and 'Ser-282' resulting in an increase in GJA1 ubiquitination and ultimately lysosomal degradation (By similarity) Acts as a transcriptional repressor. Binds to a [GC]AAA[GC] consensus sequence. Repress the expression of interferon gamma-induced genes. Seems to bind to the promoter of CCL5, DMP1, IFIH1, IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 and STAT1. Transcriptional activity is independent of kinase activity","subcellular_location":"Cytoplasm, cytoskeleton, spindle; Nucleus; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm; Membrane, caveola; Cell junction, focal adhesion","url":"https://www.uniprot.org/uniprotkb/P28482/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MAPK1","classification":"Not Classified","n_dependent_lines":172,"n_total_lines":1208,"dependency_fraction":0.1423841059602649},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000100030","cell_line_id":"CID001201","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":2}],"interactors":[{"gene":"CAPZB","stoichiometry":4.0},{"gene":"MECP2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001201","total_profiled":1310},"omim":[{"mim_id":"621174","title":"CHOLESIN; CHLSN","url":"https://www.omim.org/entry/621174"},{"mim_id":"621173","title":"G PROTEIN-COUPLED RECEPTOR 146; GPR146","url":"https://www.omim.org/entry/621173"},{"mim_id":"621172","title":"RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 39; ARHGEF39","url":"https://www.omim.org/entry/621172"},{"mim_id":"621142","title":"CHROMOSOME 15 OPEN READING FRAME 39; C15ORF39","url":"https://www.omim.org/entry/621142"},{"mim_id":"621120","title":"DELTA-LIKE NONCANONICAL NOTCH LIGAND 2; DLK2","url":"https://www.omim.org/entry/621120"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Microtubules","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Primary cilium tip","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MAPK1"},"hgnc":{"alias_symbol":["ERK","ERK2","p41mapk","MAPK2"],"prev_symbol":["PRKM2","PRKM1"]},"alphafold":{"accession":"P28482","domains":[{"cath_id":"3.30.200.20","chopping":"13-106_336-353","consensus_level":"high","plddt":93.7172,"start":13,"end":353},{"cath_id":"1.10.510.10","chopping":"109-308","consensus_level":"high","plddt":90.7579,"start":109,"end":308}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28482","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28482-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28482-F1-predicted_aligned_error_v6.png","plddt_mean":90.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MAPK1","jax_strain_url":"https://www.jax.org/strain/search?query=MAPK1"},"sequence":{"accession":"P28482","fasta_url":"https://rest.uniprot.org/uniprotkb/P28482.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28482/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28482"}},"corpus_meta":[{"pmid":"9604935","id":"PMC_9604935","title":"Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9604935","citation_count":581,"is_preprint":false},{"pmid":"16226508","id":"PMC_16226508","title":"The role of erk1 and erk2 in multiple stages of T cell development.","date":"2005","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16226508","citation_count":280,"is_preprint":false},{"pmid":"17085074","id":"PMC_17085074","title":"ERK2: a logical AND gate critical for drug-induced plasticity?","date":"2006","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17085074","citation_count":278,"is_preprint":false},{"pmid":"18594198","id":"PMC_18594198","title":"Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease.","date":"2008","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/18594198","citation_count":244,"is_preprint":false},{"pmid":"14622137","id":"PMC_14622137","title":"Essential role for ERK2 mitogen-activated protein kinase in placental development.","date":"2003","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/14622137","citation_count":241,"is_preprint":false},{"pmid":"27376062","id":"PMC_27376062","title":"ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?","date":"2016","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/27376062","citation_count":228,"is_preprint":false},{"pmid":"15096454","id":"PMC_15096454","title":"MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo.","date":"2004","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/15096454","citation_count":203,"is_preprint":false},{"pmid":"14970219","id":"PMC_14970219","title":"IQGAP1 binds ERK2 and modulates its activity.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14970219","citation_count":189,"is_preprint":false},{"pmid":"33213267","id":"PMC_33213267","title":"MAPK1/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis.","date":"2020","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/33213267","citation_count":177,"is_preprint":false},{"pmid":"19017950","id":"PMC_19017950","title":"The Erk2 MAPK regulates CD8 T cell proliferation and survival.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19017950","citation_count":170,"is_preprint":false},{"pmid":"14974085","id":"PMC_14974085","title":"Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.","date":"2004","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/14974085","citation_count":159,"is_preprint":false},{"pmid":"20011539","id":"PMC_20011539","title":"Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20011539","citation_count":148,"is_preprint":false},{"pmid":"16723731","id":"PMC_16723731","title":"PLD1 and ERK2 regulate cytosolic lipid droplet formation.","date":"2006","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/16723731","citation_count":140,"is_preprint":false},{"pmid":"21248107","id":"PMC_21248107","title":"The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation.","date":"2011","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21248107","citation_count":138,"is_preprint":false},{"pmid":"10521408","id":"PMC_10521408","title":"Identification of a cytoplasmic-retention sequence in ERK2.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10521408","citation_count":128,"is_preprint":false},{"pmid":"8798750","id":"PMC_8798750","title":"Dual leucine zipper-bearing kinase (DLK) activates p46SAPK and p38mapk but not ERK2.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8798750","citation_count":126,"is_preprint":false},{"pmid":"12032311","id":"PMC_12032311","title":"ERK2 enters the nucleus by a carrier-independent mechanism.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12032311","citation_count":125,"is_preprint":false},{"pmid":"32494004","id":"PMC_32494004","title":"CircRNA_101237 promotes NSCLC progression via the miRNA-490-3p/MAPK1 axis.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32494004","citation_count":124,"is_preprint":false},{"pmid":"28976960","id":"PMC_28976960","title":"Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28976960","citation_count":121,"is_preprint":false},{"pmid":"16567630","id":"PMC_16567630","title":"Structural basis of docking interactions between ERK2 and MAP kinase phosphatase 3.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16567630","citation_count":114,"is_preprint":false},{"pmid":"11118448","id":"PMC_11118448","title":"ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11118448","citation_count":112,"is_preprint":false},{"pmid":"24691442","id":"PMC_24691442","title":"Excess PLAC8 promotes an unconventional ERK2-dependent EMT in colon cancer.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24691442","citation_count":105,"is_preprint":false},{"pmid":"10030673","id":"PMC_10030673","title":"Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10030673","citation_count":104,"is_preprint":false},{"pmid":"10969079","id":"PMC_10969079","title":"MEKK1 binds raf-1 and the ERK2 cascade components.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10969079","citation_count":101,"is_preprint":false},{"pmid":"12594221","id":"PMC_12594221","title":"Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12594221","citation_count":100,"is_preprint":false},{"pmid":"26235619","id":"PMC_26235619","title":"Functional Redundancy of ERK1 and ERK2 MAP Kinases during Development.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26235619","citation_count":82,"is_preprint":false},{"pmid":"26190261","id":"PMC_26190261","title":"ERK2 Mediates Metabolic Stress Response to Regulate Cell Fate.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26190261","citation_count":81,"is_preprint":false},{"pmid":"14769794","id":"PMC_14769794","title":"Alternative, nonapoptotic programmed cell death: mediation by arrestin 2, ERK2, and Nur77.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14769794","citation_count":78,"is_preprint":false},{"pmid":"8013639","id":"PMC_8013639","title":"Functional divergence of the MAP kinase pathway. ERK1 and ERK2 activate specific transcription factors.","date":"1994","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8013639","citation_count":78,"is_preprint":false},{"pmid":"29125598","id":"PMC_29125598","title":"A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29125598","citation_count":76,"is_preprint":false},{"pmid":"17298299","id":"PMC_17298299","title":"Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets.","date":"2007","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/17298299","citation_count":75,"is_preprint":false},{"pmid":"11404250","id":"PMC_11404250","title":"Involvement of the MAP kinase ERK2 in MUC1 mucin signaling.","date":"2001","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11404250","citation_count":74,"is_preprint":false},{"pmid":"15882975","id":"PMC_15882975","title":"Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15882975","citation_count":73,"is_preprint":false},{"pmid":"32721402","id":"PMC_32721402","title":"Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum.","date":"2020","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32721402","citation_count":73,"is_preprint":false},{"pmid":"30728292","id":"PMC_30728292","title":"ERK2 regulates epithelial-to-mesenchymal plasticity through DOCK10-dependent Rac1/FoxO1 activation.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30728292","citation_count":69,"is_preprint":false},{"pmid":"22328529","id":"PMC_22328529","title":"ERK2 drives tumour cell migration in three-dimensional microenvironments by suppressing expression of Rab17 and liprin-β2.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22328529","citation_count":66,"is_preprint":false},{"pmid":"32485148","id":"PMC_32485148","title":"ERK2 Phosphorylates PFAS to Mediate Posttranslational Control of De Novo Purine Synthesis.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/32485148","citation_count":65,"is_preprint":false},{"pmid":"21159167","id":"PMC_21159167","title":"Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21159167","citation_count":64,"is_preprint":false},{"pmid":"25401279","id":"PMC_25401279","title":"ERK1 and ERK2 regulate chondrocyte terminal differentiation during endochondral bone formation.","date":"2015","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/25401279","citation_count":62,"is_preprint":false},{"pmid":"24550275","id":"PMC_24550275","title":"Phosphorylation releases constraints to domain motion in ERK2.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24550275","citation_count":60,"is_preprint":false},{"pmid":"18514184","id":"PMC_18514184","title":"Distinct functions for ERK1 and ERK2 in cell migration processes during zebrafish gastrulation.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18514184","citation_count":56,"is_preprint":false},{"pmid":"28393232","id":"PMC_28393232","title":"MicroRNA-329-3p targets MAPK1 to suppress cell proliferation, migration and invasion in cervical cancer.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28393232","citation_count":55,"is_preprint":false},{"pmid":"15542607","id":"PMC_15542607","title":"Adhesion stimulates direct PAK1/ERK2 association and leads to ERK-dependent PAK1 Thr212 phosphorylation.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15542607","citation_count":55,"is_preprint":false},{"pmid":"26117268","id":"PMC_26117268","title":"HOTAIR Interacting with MAPK1 Regulates Ovarian Cancer skov3 Cell Proliferation, Migration, and Invasion.","date":"2015","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/26117268","citation_count":54,"is_preprint":false},{"pmid":"27802129","id":"PMC_27802129","title":"CPEB4 is regulated during cell cycle by ERK2/Cdk1-mediated phosphorylation and its assembly into liquid-like droplets.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27802129","citation_count":53,"is_preprint":false},{"pmid":"10821702","id":"PMC_10821702","title":"Catalytic reaction pathway for the mitogen-activated protein kinase ERK2.","date":"2000","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10821702","citation_count":49,"is_preprint":false},{"pmid":"28302472","id":"PMC_28302472","title":"ERK1 and ERK2 activation modulates diet-induced obesity in mice.","date":"2017","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/28302472","citation_count":48,"is_preprint":false},{"pmid":"19861416","id":"PMC_19861416","title":"Novel nuclear nesprin-2 variants tether active extracellular signal-regulated MAPK1 and MAPK2 at promyelocytic leukemia protein nuclear bodies and act to regulate smooth muscle cell proliferation.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19861416","citation_count":47,"is_preprint":false},{"pmid":"29749377","id":"PMC_29749377","title":"P2RX7-MAPK1/2-SP1 axis inhibits MTOR independent HSPB1-mediated astroglial autophagy.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29749377","citation_count":47,"is_preprint":false},{"pmid":"18442396","id":"PMC_18442396","title":"ERK1 and ERK2 MAPK are key regulators of distinct gene sets in zebrafish embryogenesis.","date":"2008","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/18442396","citation_count":47,"is_preprint":false},{"pmid":"28689659","id":"PMC_28689659","title":"Bcl3 Phosphorylation by Akt, Erk2, and IKK Is Required for Its Transcriptional Activity.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/28689659","citation_count":46,"is_preprint":false},{"pmid":"15851480","id":"PMC_15851480","title":"Differential Involvement of ERK2 and p38 in platelet adhesion to collagen.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15851480","citation_count":46,"is_preprint":false},{"pmid":"26614994","id":"PMC_26614994","title":"Expression of MAPK1 in cervical cancer and effect of MAPK1 gene silencing on epithelial-mesenchymal transition, invasion and metastasis.","date":"2015","source":"Asian Pacific journal of tropical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26614994","citation_count":45,"is_preprint":false},{"pmid":"35026514","id":"PMC_35026514","title":"Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665/miR-665/MAPK1 axis.","date":"2021","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35026514","citation_count":44,"is_preprint":false},{"pmid":"18378228","id":"PMC_18378228","title":"ERK2 protein regulates the proliferation of human mesenchymal stem cells without affecting their mobilization and differentiation potential.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18378228","citation_count":43,"is_preprint":false},{"pmid":"29118671","id":"PMC_29118671","title":"miR-422a inhibits cell proliferation in colorectal cancer by targeting AKT1 and MAPK1.","date":"2017","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/29118671","citation_count":42,"is_preprint":false},{"pmid":"29335299","id":"PMC_29335299","title":"HOTAIR contributes to cell proliferation and metastasis of cervical cancer via targetting miR-23b/MAPK1 axis.","date":"2018","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/29335299","citation_count":41,"is_preprint":false},{"pmid":"16045329","id":"PMC_16045329","title":"Proximity-induced catalysis by the protein kinase ERK2.","date":"2005","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/16045329","citation_count":40,"is_preprint":false},{"pmid":"9295311","id":"PMC_9295311","title":"Activation of the mitogen-activated protein kinase ERK2 by the chemoattractant folic acid in Dictyostelium.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9295311","citation_count":40,"is_preprint":false},{"pmid":"26336084","id":"PMC_26336084","title":"ERK1 and ERK2 present functional redundancy in tetrapods despite higher evolution rate of ERK1.","date":"2015","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/26336084","citation_count":40,"is_preprint":false},{"pmid":"31075732","id":"PMC_31075732","title":"miR-141-5p regulate ATF2 via effecting MAPK1/ERK2 signaling to promote preeclampsia.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31075732","citation_count":39,"is_preprint":false},{"pmid":"30693181","id":"PMC_30693181","title":"Gene Silencing via PDA/ERK2-siRNA-Mediated Electrospun Fibers for Peritendinous Antiadhesion.","date":"2018","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/30693181","citation_count":39,"is_preprint":false},{"pmid":"23444405","id":"PMC_23444405","title":"Erk1 and Erk2 are required for maintenance of hematopoietic stem cells and adult hematopoiesis.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23444405","citation_count":38,"is_preprint":false},{"pmid":"29137432","id":"PMC_29137432","title":"MiR-143 inhibits endometrial cancer cell proliferation and metastasis by targeting MAPK1.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29137432","citation_count":37,"is_preprint":false},{"pmid":"23271465","id":"PMC_23271465","title":"Proteomic and functional analyses reveal MAPK1 regulates milk protein synthesis.","date":"2012","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/23271465","citation_count":36,"is_preprint":false},{"pmid":"20825492","id":"PMC_20825492","title":"ERK1 and ERK2 are required for radial glial maintenance and cortical lamination.","date":"2010","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/20825492","citation_count":36,"is_preprint":false},{"pmid":"26760678","id":"PMC_26760678","title":"MAPK1/3 regulate hepatic lipid metabolism via ATG7-dependent autophagy.","date":"2016","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/26760678","citation_count":35,"is_preprint":false},{"pmid":"30657558","id":"PMC_30657558","title":"MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30657558","citation_count":34,"is_preprint":false},{"pmid":"31311868","id":"PMC_31311868","title":"Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31311868","citation_count":34,"is_preprint":false},{"pmid":"32231737","id":"PMC_32231737","title":"Circular RNA MAN2B2 promotes cell proliferation of hepatocellular carcinoma cells via the miRNA-217/MAPK1 axis.","date":"2020","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32231737","citation_count":33,"is_preprint":false},{"pmid":"32187556","id":"PMC_32187556","title":"Mechanical Stress Regulates Epithelial Tissue Integrity and Stiffness through the FGFR/Erk2 Signaling Pathway during Embryogenesis.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32187556","citation_count":33,"is_preprint":false},{"pmid":"32471201","id":"PMC_32471201","title":"Liver Fibrosis and Inflammation under the Control of ERK2.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32471201","citation_count":32,"is_preprint":false},{"pmid":"10593929","id":"PMC_10593929","title":"Activated ERK2 interacts with and phosphorylates the docking protein GAB1.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10593929","citation_count":32,"is_preprint":false},{"pmid":"38169625","id":"PMC_38169625","title":"MAPK1 Mediates MAM Disruption and Mitochondrial Dysfunction in Diabetic Kidney Disease via the PACS-2-Dependent Mechanism.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38169625","citation_count":30,"is_preprint":false},{"pmid":"23946386","id":"PMC_23946386","title":"ERK2-mediated phosphorylation of Par3 regulates neuronal polarization.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23946386","citation_count":30,"is_preprint":false},{"pmid":"26861188","id":"PMC_26861188","title":"Naringenin targets ERK2 and suppresses UVB-induced photoaging.","date":"2016","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26861188","citation_count":29,"is_preprint":false},{"pmid":"21985012","id":"PMC_21985012","title":"Resting and active states of the ERK2:HePTP complex.","date":"2011","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/21985012","citation_count":28,"is_preprint":false},{"pmid":"36103025","id":"PMC_36103025","title":"LINC00511 promotes cervical cancer progression by regulating the miR-497-5p/MAPK1 axis.","date":"2022","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/36103025","citation_count":27,"is_preprint":false},{"pmid":"35768803","id":"PMC_35768803","title":"The role of ERK-1 and ERK-2 gene polymorphisms in PCOS pathogenesis.","date":"2022","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/35768803","citation_count":27,"is_preprint":false},{"pmid":"34668273","id":"PMC_34668273","title":"EZH2 upregulates the expression of MAPK1 to promote intervertebral disc degeneration via suppression of miR-129-5p.","date":"2022","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34668273","citation_count":27,"is_preprint":false},{"pmid":"37817112","id":"PMC_37817112","title":"MAPK1 promotes the metastasis and invasion of gastric cancer as a bidirectional transcription factor.","date":"2023","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37817112","citation_count":26,"is_preprint":false},{"pmid":"23820584","id":"PMC_23820584","title":"KRAS and MAPK1 gene amplification in type II ovarian carcinomas.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23820584","citation_count":26,"is_preprint":false},{"pmid":"28860596","id":"PMC_28860596","title":"MAPK1 of Leishmania donovani interacts and phosphorylates HSP70 and HSP90 subunits of foldosome complex.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28860596","citation_count":26,"is_preprint":false},{"pmid":"16420578","id":"PMC_16420578","title":"ERK2 activation in arteriolar and venular murine thrombosis: platelet receptor GPIb vs. P2X.","date":"2006","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/16420578","citation_count":26,"is_preprint":false},{"pmid":"33537828","id":"PMC_33537828","title":"MicroRNA‑186‑5p downregulation inhibits osteoarthritis development by targeting MAPK1.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/33537828","citation_count":26,"is_preprint":false},{"pmid":"25730857","id":"PMC_25730857","title":"Structural assembly of the signaling competent ERK2-RSK1 heterodimeric protein kinase complex.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25730857","citation_count":25,"is_preprint":false},{"pmid":"11679970","id":"PMC_11679970","title":"Defective mitogen-activated protein kinase (ERK2) signaling in gastric mucosa of portal hypertensive rats: potential therapeutic implications.","date":"2001","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11679970","citation_count":25,"is_preprint":false},{"pmid":"16324895","id":"PMC_16324895","title":"Quantifying ERK2-protein interactions by fluorescence anisotropy: PEA-15 inhibits ERK2 by blocking the binding of DEJL domains.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16324895","citation_count":24,"is_preprint":false},{"pmid":"19277491","id":"PMC_19277491","title":"Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor.","date":"2009","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/19277491","citation_count":23,"is_preprint":false},{"pmid":"30696942","id":"PMC_30696942","title":"A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability.","date":"2019","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/30696942","citation_count":23,"is_preprint":false},{"pmid":"28627458","id":"PMC_28627458","title":"siRNA-loaded biodegradable nanocarriers for therapeutic MAPK1 silencing against cisplatin-induced ototoxicity.","date":"2017","source":"International journal of pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/28627458","citation_count":23,"is_preprint":false},{"pmid":"27121568","id":"PMC_27121568","title":"A PARP1-ERK2 synergism is required for the induction of LTP.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27121568","citation_count":22,"is_preprint":false},{"pmid":"25803100","id":"PMC_25803100","title":"Both ERK1 and ERK2 are required for enterovirus 71 (EV71) efficient replication.","date":"2015","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/25803100","citation_count":22,"is_preprint":false},{"pmid":"33173004","id":"PMC_33173004","title":"Loss of the Conserved Alveolate Kinase MAPK2 Decouples Toxoplasma Cell Growth from Cell Division.","date":"2020","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/33173004","citation_count":21,"is_preprint":false},{"pmid":"29551366","id":"PMC_29551366","title":"Dictyostelium Erk2 is an atypical MAPK required for chemotaxis.","date":"2018","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/29551366","citation_count":21,"is_preprint":false},{"pmid":"26872611","id":"PMC_26872611","title":"MAPK1/ERK2 as novel target genes for pain in head and neck cancer patients.","date":"2016","source":"BMC genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26872611","citation_count":21,"is_preprint":false},{"pmid":"28915648","id":"PMC_28915648","title":"Synergistic suppression of t(8;21)-positive leukemia cell growth by combining oridonin and MAPK1/ERK2 inhibitors.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28915648","citation_count":21,"is_preprint":false},{"pmid":"38211649","id":"PMC_38211649","title":"N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128-3p/MAPK1 axis.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38211649","citation_count":20,"is_preprint":false},{"pmid":"18572386","id":"PMC_18572386","title":"COX2 expression and Erk1/Erk2 activity mediate Cot-induced cell migration.","date":"2008","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/18572386","citation_count":20,"is_preprint":false},{"pmid":"25639353","id":"PMC_25639353","title":"Active ERK2 is sufficient to mediate growth arrest and differentiation signaling.","date":"2015","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/25639353","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52072,"output_tokens":9082,"usd":0.146223,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19269,"output_tokens":5467,"usd":0.11651,"stage2_stop_reason":"end_turn"},"total_usd":0.262733,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"Phosphorylated ERK2 forms homodimers with both phosphorylated and unphosphorylated ERK2 partners; disruption of dimerization by mutagenesis reduces nuclear accumulation, establishing that dimerization is required for ligand-dependent nuclear translocation. Crystal structure of phosphorylated ERK2 reveals the structural basis for dimerization.\",\n      \"method\": \"Microinjection of ERK2 into cells, site-directed mutagenesis, crystal structure of phospho-ERK2\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with mutagenesis and functional nuclear-localization assay in a single rigorous study\",\n      \"pmids\": [\"9604935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Residues 312–320 of ERK2 constitute a cytoplasmic-retention sequence that mediates association with MEK1, keeping ERK2 in the cytosol in resting cells; residues 321–327 are required for nuclear translocation upon mitogenic stimulation. Key acidic residues at positions 316, 319, and 320 are essential for cytosolic retention.\",\n      \"method\": \"GFP-ERK2 fusion constructs expressed in CHO cells, alanine-scanning mutagenesis, co-expression with MEK1, fluorescence microscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of specific residues with direct functional readout (cytosolic vs. nuclear localization), single lab but multiple mutant constructs and orthogonal approaches\",\n      \"pmids\": [\"10521408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ERK2 enters the nucleus by a carrier- and energy-independent mechanism involving direct binding to nucleoporins of the nuclear pore complex, competing with canonical transport factors for pore access.\",\n      \"method\": \"In vitro nuclear import assay with GFP-ERK2, wheat germ agglutinin inhibition, recombinant transport factor competition, direct binding to purified nucleoporin\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro import assay with multiple orthogonal inhibition approaches and direct nucleoporin binding experiment\",\n      \"pmids\": [\"12032311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ERK2 catalytic mechanism proceeds via rapid-equilibrium ATP binding followed by diffusion-limited MBP binding and rate-limiting phosphoryl transfer (kcat ~10 s⁻¹), with product release faster than phosphoryl transfer.\",\n      \"method\": \"Steady-state kinetics and solvent viscosimetry with purified ERK2, MBP, and ERKtide peptide substrates\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstituted kinetic analysis with viscosimetric probes; single lab but multiple substrates and rigorous mechanistic dissection\",\n      \"pmids\": [\"10821702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Crystal structure of ERK2 bound to the KIM peptide of MAP kinase phosphatase 3 (MKP3) reveals that the docking site on ERK2 comprises a highly acidic patch and a hydrophobic groove that engage the basic and hydrophobic residues of the KIM sequence; this docking site is distinct from the catalytic pocket.\",\n      \"method\": \"X-ray crystallography of ERK2:KIM peptide complex\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with validation against existing biochemical data; replicated mechanistic insight across multiple MAPK family members\",\n      \"pmids\": [\"16567630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Dual phosphorylation of ERK2 by MEK1 releases conformational constraints at the hinge between N- and C-terminal domains, inducing global two-state conformational exchange (kex ~300 s⁻¹) throughout the kinase core including the catalytic pocket, thereby promoting catalytic activity.\",\n      \"method\": \"NMR ¹³C relaxation dispersion (Ile/Leu/Val methyl side chains), hinge-mutant ERK2 engineering\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR with mutagenesis validation, single lab but multiple ERK2 states and engineered mutant corroboration\",\n      \"pmids\": [\"24550275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERK inhibitors Vertex-11e and SCH772984 exploit two distinct conformational states (L and R) of active 2P-ERK2: Vertex-11e stabilizes the R (domain-closed, catalytically competent) state while a SCH772984 analog blocks domain closure; these conformational differences differentially regulate MAP kinase phosphatase-mediated dephosphorylation of ERK2.\",\n      \"method\": \"X-ray crystallography of 2P-ERK2 complexes, NMR hydrogen-exchange MS (HX-MS), kinase conformation analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple crystal structures plus HX-MS, mechanistic validation of opposing conformational effects on phosphatase activity\",\n      \"pmids\": [\"31311868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IQGAP1 directly binds ERK2 in vitro and co-immunoprecipitates with endogenous ERK2 from human breast epithelial cells; manipulation of IQGAP1 levels modulates growth-factor-stimulated ERK1/2 activity, and an IQGAP1 construct lacking the ERK2-binding region fails to interfere with ERK activation.\",\n      \"method\": \"In vitro pull-down with purified proteins, co-immunoprecipitation from cell lysates, overexpression/knockdown of IQGAP1, kinase activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus in vitro direct-binding assay plus functional kinase activity readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"14970219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Endogenous MEKK1 binds endogenous ERK2, MEK1, and Raf-1, indicating that MEKK1 can serve as a scaffold assembling all three kinases of the ERK MAP kinase module.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins from cell lysates\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — endogenous Co-IP supporting scaffold function; single lab, single method\",\n      \"pmids\": [\"10969079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Using an engineered ERK2 (Q103G) that accepts a bulky ATP analog, EDD (ubiquitin E3 ligase) and nucleoporin Tpr were identified as novel direct ERK2 substrates; EDD phosphorylation by ERK2 was confirmed both in vitro and in vivo.\",\n      \"method\": \"Chemical genetics (engineered kinase + ATP analog), phosphorylation of ERK2-associated proteins in COS-1 cells, in vitro kinase assay, in vivo phosphorylation validation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — chemical-genetic substrate ID method with in vitro and in vivo validation; single lab with two orthogonal confirmation approaches\",\n      \"pmids\": [\"12594221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Phosphorylated (active) ERK2 directly associates with GAB1 via its MET-binding domain without requiring a third protein; ERK2 phosphorylates GAB1 in vitro and in cells, with new phosphorylation sites appearing upon MEK1 co-transfection.\",\n      \"method\": \"GST pull-down with bacterially expressed proteins, co-immunoprecipitation in A293 cells, in vitro kinase assay, phosphopeptide mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vitro binding confirmed with purified proteins, plus cellular Co-IP and in vivo phosphorylation; single lab\",\n      \"pmids\": [\"10593929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Adhesion stimulates a direct physical interaction between PAK1 and ERK2; ERK2 phosphorylates PAK1 at Thr212 in vitro and in PDGF-treated smooth muscle cells in an adhesion- and MEK/ERK-dependent manner; a phosphomimic PAK1-T212E attenuates downstream ERK signaling, suggesting a negative feedback loop.\",\n      \"method\": \"Co-immunoprecipitation, far-Western analysis, peptide mapping of ERK2 binding site, in vitro kinase assay, SRE-luciferase reporter, immunofluorescence co-localization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro binding and phosphorylation confirmed with in vivo validation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15542607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ERK2 mediates proximity-induced (docking-dependent) catalysis: the pnt domain of substrate EtsDelta138 docks outside the active site, increasing effective concentration of the phosphorylatable TP motif near the catalytic pocket; disruption of the pnt-domain interaction (F120A) reduces binding 10-fold without affecting kcat, while mutagenesis of the TP motif decreases kcat without affecting docking.\",\n      \"method\": \"In vitro kinase assays with ERK2 and domain/point mutants of EtsDelta138, equilibrium binding measurements\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with systematic mutagenesis of both enzyme substrate-recognition domain and substrate docking motif; single lab, multiple mutants\",\n      \"pmids\": [\"16045329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of the ERK2–RSK1 heterodimeric complex captures a precatalytic state where the RSK1 activation loop faces the ERK2 catalytic site; the MAPK-binding linear motif of RSK1 interacting with the ERK2 docking groove is the primary determinant of complex formation, and domain contacts between the kinase cores shift the complex into a catalytically competent state.\",\n      \"method\": \"X-ray crystallography, molecular dynamics simulation, biochemical assays, cellular signaling studies\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with MD simulation and biochemical/cellular validation; multiple orthogonal methods\",\n      \"pmids\": [\"25730857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SAXS analysis shows the resting-state ERK2:HePTP complex is extended and dynamic, whereas the active-state complex is compact and ordered, demonstrating that these regulatory complexes undergo significant dynamic structural rearrangement in solution.\",\n      \"method\": \"Small-angle X-ray scattering (SAXS) with EROS ensemble refinement\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — structural method (SAXS) on purified complexes; single lab, no orthogonal functional validation\",\n      \"pmids\": [\"21985012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ERK2 (but not ERK1, JNK1, JNK2, p38α, or p38β) is required for cytosolic lipid droplet formation; ERK2 acts downstream of PLD1, and ERK2 increases phosphorylation of dynein, which increases dynein association with ADRP-containing lipid droplets; antibody inhibition of dynein strongly blocks lipid droplet formation.\",\n      \"method\": \"Overexpression, siRNA knockdown, microinjection of ERK2 and PLD1, pharmacological inhibition, dynein phosphorylation assay, antibody microinjection\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal manipulations (OE, KD, microinjection) with pathway ordering; single lab\",\n      \"pmids\": [\"16723731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERK2 directly interacts with Par3 and phosphorylates it at Ser-1116; phosphorylated Par3 accumulates at axonal tips but its interaction with KIF3A is inhibited, slowing axonal transport and impairing neuronal polarization in cultured hippocampal neurons and mouse cortical neurons in vivo.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, phosphomimic/phospho-null mutants, RNAi rescue experiments in cultured neurons and in vivo cortical neurons\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct binding, in vitro phosphorylation, phosphomimic rescue, and in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"23946386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ERK2 (but not ERK1) phosphorylates PFAS (phosphoribosylformylglycinamidine synthase) at Thr619 to stimulate de novo purine synthesis flux; non-phosphorylatable PFAS-T619A decreases purine synthesis and reduces RAS-dependent cancer cell colony formation and tumor growth.\",\n      \"method\": \"In vitro kinase assay with purified ERK2, ¹³C metabolic flux analysis, phosphomutant expression, colony formation and xenograft tumor assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus metabolic flux measurement plus phosphomutant functional studies in cells and in vivo; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"32485148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MAPK1/ERK2 phosphorylates ULK1, triggering its interaction with the E3 ligase BTRC and subsequent K48-linked ubiquitination and proteasomal degradation, thereby attenuating mitophagy and promoting NLRP3 inflammasome activation and breast cancer bone metastasis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination assay, MEK inhibitor (trametinib) rescue, xenograft mouse model, human breast cancer tissue correlation\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical pathway dissection with Co-IP, pharmacological rescue, and in vivo validation; single lab\",\n      \"pmids\": [\"33213267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ERK2, together with Akt and IKK1/2, phosphorylates Bcl3 at Ser114 and Ser446; ERK2/IKK1/2-mediated phosphorylation converts Bcl3 from an IκB-like inhibitor into a transcriptional co-regulator by facilitating its recruitment to DNA; cells expressing S114A/S446A Bcl3 show proliferation and migration defects.\",\n      \"method\": \"In vitro kinase assays, phosphomutant expression, co-immunoprecipitation, DNA-binding assays, cellular proliferation/migration assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus phosphomutant functional studies with defined cellular readouts; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"28689659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ERK2 and Cdk1 hyperphosphorylate CPEB4 in M-phase to maintain it as a monomer and activate its mRNA-translation regulatory function; unphosphorylated CPEB4 phase-separates into inactive liquid-like droplets through its intrinsically disordered N-terminal domain.\",\n      \"method\": \"In vitro phosphorylation assays, phosphomutant analysis, phase-separation assays, cell cycle synchronization, fluorescence microscopy\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase and phase-separation assays with cell-cycle validation; single lab\",\n      \"pmids\": [\"27802129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERK2 (but not ERK1) binds Shank3 and phosphorylates it at three residues to promote poly-ubiquitination-dependent proteasomal degradation of Shank3; genetic deletion or pharmacological inhibition of ERK2 increases Shank3 abundance in vivo.\",\n      \"method\": \"Kinome-wide siRNA screen, co-immunoprecipitation, in vitro kinase assay, ERK2 knockout mice, pharmacological inhibition\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — screen followed by direct biochemical validation (Co-IP, in vitro phosphorylation), in vivo knockout confirmation; multiple orthogonal methods\",\n      \"pmids\": [\"30696942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERK2 induces EMT by upregulating Dock10 (a Rac1/Cdc42 GEF), which activates Rac1/JNK signaling, leading to increased FoxO1 expression; ERK2-dependent FoxO1 regulation promotes epithelial-to-mesenchymal plasticity.\",\n      \"method\": \"Global gene expression analysis (ERK2-specific), co-immunoprecipitation, RNAi, reporter assays, cell migration assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by gene expression profiling followed by functional RNAi rescue; single lab\",\n      \"pmids\": [\"30728292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Under sustained metabolic (low-glucose) stress, MEK1/ERK2 isoform-specific signaling induces GCN2/eIF2α phosphorylation and ATF4 expression, which overrides PERK/Akt-mediated survival and induces apoptosis through ATF4-dependent pro-apoptotic factors (Bid, Trb3); ERK2 activation also alters TCA cycle and amino acid metabolism.\",\n      \"method\": \"Isoform-specific knockdown/overexpression, phosphoprotein analysis, metabolomics (TCA cycle, amino acid profiling), apoptosis assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-selective KD with metabolic and signaling readouts; single lab, multiple orthogonal measurements\",\n      \"pmids\": [\"26190261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Mitochondrial localization of active ERK2 (but not kinase-dead ERK2) is sufficient to induce mitophagy and autophagic cell death; constitutively active ERK2 localizes more strongly to mitochondria than WT ERK2, and these mitochondria-associated ERK2 granules undergo autophagic degradation.\",\n      \"method\": \"GFP-ERK2 fusion constructs (WT, CA, KD), live-cell fluorescence microscopy, co-localization with mitochondrial and autophagolysosomal markers, bafilomycin-A inhibitor experiments, LC3 autophagy marker analysis\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization imaging with kinase-dead vs. active mutant comparison and pharmacological validation; single lab\",\n      \"pmids\": [\"18594198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ERK2 kinase activity drives a specific phenotype switch (transcriptional reprogramming resembling EMT, including shutdown of MITF) that underlies drug addiction in BRAF-inhibitor-resistant melanoma cells; disruption of an ERK2-JUNB-FRA1 signaling pathway allows addicted cells to survive drug withdrawal.\",\n      \"method\": \"Unbiased CRISPR-Cas9 knockout screen, ERK2-specific rescue experiments, in vitro and in vivo (mouse) models, patient tissue analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — unbiased genome-wide screen validated by rescue experiments in cells and mice; replicated across multiple resistance mechanisms\",\n      \"pmids\": [\"28976960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PLAC8 directly binds and inactivates the ERK2 phosphatase DUSP6 in vitro, thereby increasing phospho-ERK2 levels; ERK2 knockdown reverses PLAC8-induced EMT features (restored CDH1, suppressed CDH3/VIM/ZEB1), placing ERK2 downstream of PLAC8-DUSP6 in an unconventional EMT pathway in colon cancer.\",\n      \"method\": \"In vitro DUSP6 activity assay with recombinant PLAC8, ERK2 knockdown, xenograft tumor model, MultiOmyx multiplex immunofluorescence\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vitro phosphatase inhibition assay plus ERK2 KD epistasis plus in vivo validation; single lab\",\n      \"pmids\": [\"24691442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Nesprin-2 acts as a nuclear scaffold that tethers active ERK1/2 at PML nuclear bodies; knockdown or dominant-negative disruption of nesprin-2 augments ERK1/2 nuclear signaling (increased SP1 activity and ELK1 phosphorylation) and increases cell proliferation; this function is mediated by nuclear nesprin-2 isoforms lacking the KASH domain.\",\n      \"method\": \"Immunofluorescence co-localization, GST pull-down, co-immunoprecipitation, siRNA knockdown, dominant-negative overexpression, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and pull-down with functional readouts; single lab, multiple complementary approaches\",\n      \"pmids\": [\"19861416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PARP1 binds phosphorylated ERK2 in neuronal chromatin upon stimulation; ERK2-induced PARP1 activation renders immediate early gene (IEG) promoters accessible to phospho-ERK2, mediating IEG expression required for LTP; PARP1 inhibition or deletion abrogates ERK2 recruitment to IEG promoters and prevents LTP generation.\",\n      \"method\": \"Co-immunoprecipitation of chromatin-bound proteins, PARP1 inhibition/knockdown/knockout, ERK2 chromatin-immunoprecipitation, LTP electrophysiology in hippocampal slices\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating ERK2 recruitment to IEG promoters with PARP1 dependency; multiple loss-of-function approaches; single lab\",\n      \"pmids\": [\"27121568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Noonan syndrome PTPN11 (SHP2) gain-of-function mutants cause prolonged ERK2/MAPK1 activation in a ligand (EGF)-dependent, GAB1-docking-dependent manner; co-expression of GAB1-FF (lacking SHP2-binding motifs) dramatically reduces ERK2 activation, establishing the SHP2→GAB1→ERK2 pathway axis.\",\n      \"method\": \"Phosphatase activity assays, ERK2 kinase assays, co-immunoprecipitation of SHP2 with GAB1, dominant-negative GAB1 epistasis, cell proliferation assays\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical pathway epistasis with multiple mutants and direct kinase/phosphatase assays; single lab\",\n      \"pmids\": [\"14974085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In Xenopus embryos, mechanical forces (centrifugal, compression, stretching) activate ERK2 via FGFR1 independently of FGF ligands; ERK2 activation remodels cytoskeletal proteins (F-actin, C-cadherin, ZO-1) to enhance cellular junctions and tissue stiffening.\",\n      \"method\": \"Xenopus embryo mechanical stimulation, phosphoproteome analysis, FGFR1 inhibition, fluorescence imaging of cytoskeletal markers\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomics-guided functional analysis with pharmacological epistasis in a developmental model; single lab\",\n      \"pmids\": [\"32187556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ERK2 (but not ERK1) silencing inhibits invasive migration in 3D matrices; ERK2 re-expression (not ERK1) restores invasion; ERK2 suppresses expression of Rab17 and liprin-β2, which inhibit invasion; knockdown of either Rab17 or liprin-β2 restores invasiveness of ERK2-depleted cells.\",\n      \"method\": \"siRNA knockdown, isoform-specific rescue, 3D matrix migration assays, gene expression arrays, secondary knockdown epistasis\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-selective rescue with downstream gene epistasis; single lab, multiple cancer cell lines\",\n      \"pmids\": [\"22328529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERK2 directly interacts with and phosphorylates Par3 at Ser-1116, inhibiting Par3–KIF3A interaction; phosphomimic Par3-S1116D shows reduced KIF3A binding and slower axonal transport, impairing neuronal polarization in hippocampal neurons and cortical projection neurons in vivo.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, phosphomimic/phospho-null mutants expressed in cultured neurons and in vivo mouse cortex via in utero electroporation, RNAi rescue\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro phosphorylation with site identification, phosphomutant functional rescue in cultured neurons and in vivo; multiple orthogonal methods, replicated in two neuronal systems\",\n      \"pmids\": [\"23946386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PEA-15 sequesters ERK2 in the cytoplasm by competing with DEJL-domain-containing substrates/activators for binding to ERK2; the C-terminus of PEA-15 (residues 121–129) constitutes a reverse DEJL domain mediating one arm of a bidentate interaction with ERK2.\",\n      \"method\": \"Fluorescence anisotropy binding assays with purified ERK2 and PEA-15/peptides, competition experiments with DEJL-derived peptides\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — quantitative in vitro binding assay with mechanistic model; single lab, single method\",\n      \"pmids\": [\"16324895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"High glucose conditions increase MAPK1 activity, which lowers PACS-2 (a MAM tethering protein) levels, causing mitochondria-associated ER membrane (MAM) disruption and mitochondrial fragmentation in renal tubular cells; inhibition of MAPK1 restores PACS-2 and protects against MAM loss and mitochondrial fragmentation in diabetic mice.\",\n      \"method\": \"Diabetic mouse and human kidney tissue analysis, HK-2 cell high-glucose model, MAPK1 inhibition (pharmacological), PACS-2 rescue overexpression\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function pharmacological approach with PACS-2 rescue in cells and in vivo; single lab, multiple models\",\n      \"pmids\": [\"38169625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MAPK1/ERK2 activation ameliorates hepatic steatosis through ATG7-dependent autophagy; knockdown of MAPK1/3 promotes liver steatosis, reduces autophagic flux and ATG7 levels in primary hepatocytes; blockade of autophagy (chloroquine or ATG7 knockdown) reverses the anti-steatosis effect of MAPK1/3 activation.\",\n      \"method\": \"Adenoviral MAPK1/3 activation in db/db mice, siRNA knockdown, autophagic flux assays, ATG7 expression analysis, pharmacological autophagy blockade\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function and loss-of-function with epistasis through ATG7 knockdown; single lab, in vitro and in vivo\",\n      \"pmids\": [\"26760678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MAPK1 binds to promoter regions of target genes in gastric cancer cells and functions as a bidirectional transcription factor (independent of its kinase role), upregulating KRT13, KRT6A, KRT81, MYH15, STARD4, SYTL4, TMEM267 and downregulating FGG, thereby promoting cell motility and invasion.\",\n      \"method\": \"ChIP-seq, RNA-seq, ChIP assays, chromatin immunoprecipitation confirming MAPK1 at promoters, cell proliferation and migration assays\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq and ChIP with functional readouts; single lab, single cell line\",\n      \"pmids\": [\"37817112\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ERK2/MAPK1 is a dual-specificity-regulated serine/threonine kinase that is activated by MEK1/2-mediated dual phosphorylation on TEY residues, triggering global conformational changes that enhance catalytic activity; phospho-ERK2 homodimerizes and translocates to the nucleus by binding directly to nuclear pore complex nucleoporins (carrier-independent), while in resting cells it is held in the cytoplasm via a C-terminal retention sequence that mediates MEK1 association; in the nucleus it phosphorylates substrates (e.g., ELK-1, PARP1-associated IEG promoters, Par3, CPEB4) docked through a conserved acidic-patch/hydrophobic-groove KIM-docking site, and in the cytoplasm it phosphorylates diverse substrates including PFAS (stimulating de novo purine synthesis), ULK1 (triggering its ubiquitin-dependent degradation and limiting mitophagy), PAK1 (negative feedback), Shank3 (promoting degradation), and Par3 (regulating axon polarity); its activity is spatially organized by scaffold proteins such as IQGAP1, nesprin-2 (at PML nuclear bodies), and MEKK1, and is negatively regulated by phosphatases (MKP3/DUSP6) that engage the same KIM docking groove, with conformational selection by small-molecule inhibitors further modulating dephosphorylation susceptibility.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MAPK1/ERK2 is a serine/threonine kinase that serves as a terminal effector of the ERK MAP kinase module, converting mitogenic and mechanical inputs into transcriptional, metabolic, and cytoskeletal outputs [#8, #30]. Activation is governed by MEK1-mediated dual phosphorylation, which releases conformational constraints at the hinge between the N- and C-terminal lobes to drive global two-state conformational exchange throughout the catalytic core and promote activity [#5], with catalysis proceeding through rapid-equilibrium ATP binding followed by rate-limiting phosphoryl transfer [#3]. Substrate and regulator engagement is directed by a docking site distinct from the catalytic pocket—an acidic patch and hydrophobic groove that bind KIM/linear motifs of partners such as the phosphatase MKP3 and the kinase RSK1, the latter captured in a precatalytic heterodimeric state [#4, #13]; proximity-based docking increases the effective concentration of phosphoacceptor motifs near the active site [#12]. Subcellular targeting is tightly controlled: a C-terminal retention sequence (residues 312–320) holds ERK2 in the cytosol via MEK1 association in resting cells, while activation promotes homodimerization and carrier-independent nuclear entry through direct nucleoporin binding [#0, #1, #2]. ERK2 phosphorylates a broad substrate repertoire to control diverse processes—PFAS to stimulate de novo purine synthesis [#17], ULK1 to trigger its ubiquitin-dependent degradation and restrain mitophagy [#18], Par3 to regulate axonal transport and neuronal polarity [#16, #32], CPEB4 to control its phase behavior and mRNA-translation activity [#20], Shank3 and PAK1 to drive their degradation or feedback inhibition [#21, #11], and transcriptional regulators including Bcl3 and the IEG machinery via PARP1 [#19, #28]. ERK2 activity is spatially organized by scaffolds and tethers including IQGAP1, MEKK1, and nesprin-2 at PML nuclear bodies [#7, #8, #27], and counter-regulated by phosphatases whose dephosphorylation efficiency depends on ERK2 conformational state [#6, #26]. ERK2-specific signaling drives epithelial-mesenchymal plasticity, invasion, and BRAF-inhibitor-resistant melanoma phenotypes, frequently distinguishing it functionally from ERK1 [#25, #31, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established how active ERK2 reaches the nucleus, resolving whether nuclear accumulation required oligomerization—dimerization of phospho-ERK2 was shown to be necessary for ligand-dependent nuclear translocation.\",\n      \"evidence\": \"Microinjection, site-directed mutagenesis, and crystal structure of phospho-ERK2\",\n      \"pmids\": [\"9604935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the nuclear import machinery used\", \"Dimerization-independent functions not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined the molecular basis for cytoplasmic retention versus nuclear targeting, mapping a C-terminal retention sequence that anchors ERK2 to MEK1 in resting cells and a separate segment required for translocation.\",\n      \"evidence\": \"GFP-ERK2 fusions in CHO cells with alanine-scanning mutagenesis and MEK1 co-expression\",\n      \"pmids\": [\"10521408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How activation overrides retention not mechanistically resolved\", \"Did not address the translocation machinery\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Addressed how ERK2 catalysis is timed and how the kinase module assembles—kinetic dissection set phosphoryl transfer as rate-limiting, and MEKK1 was shown to bind ERK2, MEK1, and Raf-1 as a candidate scaffold.\",\n      \"evidence\": \"Steady-state kinetics with viscosimetry on purified ERK2; endogenous co-immunoprecipitation\",\n      \"pmids\": [\"10821702\", \"10969079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MEKK1 scaffold stoichiometry and cellular requirement not established\", \"Kinetics on physiological substrates beyond MBP/peptide limited\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Determined the mechanism of ERK2 nuclear import, showing it occurs by carrier- and energy-independent direct binding to nucleoporins rather than canonical import factors.\",\n      \"evidence\": \"Reconstituted in vitro import assay with WGA inhibition, transport-factor competition, and direct nucleoporin binding\",\n      \"pmids\": [\"12032311\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with dimerization requirement for import not fully integrated\", \"Which nucleoporins are physiologically rate-limiting unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Resolved the structural basis of substrate/regulator selection, showing a docking site (acidic patch plus hydrophobic groove) distinct from the catalytic pocket engages KIM motifs.\",\n      \"evidence\": \"X-ray crystallography of ERK2:MKP3 KIM peptide complex\",\n      \"pmids\": [\"16567630\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not capture full-length phosphatase or substrate complex dynamics\", \"Selectivity determinants among different KIM motifs not exhaustively defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Clarified how docking translates into catalytic efficiency, demonstrating proximity-induced catalysis where substrate domains dock outside the active site to raise effective concentration of the phosphoacceptor motif.\",\n      \"evidence\": \"In vitro kinase assays with domain/point mutants of EtsDelta138 and binding measurements\",\n      \"pmids\": [\"16045329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality across all substrate classes not tested\", \"In vitro reconstitution only\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Explained how phosphorylation activates the kinase at the conformational level, showing TEY phosphorylation releases hinge constraints to drive global two-state exchange that reaches the catalytic pocket.\",\n      \"evidence\": \"NMR 13C relaxation dispersion with hinge-mutant ERK2 engineering\",\n      \"pmids\": [\"24550275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct link between specific conformer and substrate turnover rates not fully quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected ERK2 conformational state to drug action and regulation, showing inhibitors stabilizing distinct L/R states differentially affect phosphatase-mediated dephosphorylation.\",\n      \"evidence\": \"X-ray crystallography and HX-MS of 2P-ERK2 inhibitor complexes\",\n      \"pmids\": [\"31311868\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell consequences of conformation-selective dephosphorylation not measured\", \"Effect on individual substrate selection unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified ERK2 scaffolds and feedback substrates, establishing IQGAP1 as a direct binding partner modulating ERK1/2 activity and PAK1 as an adhesion-dependent substrate forming a negative feedback loop.\",\n      \"evidence\": \"In vitro pull-down, reciprocal Co-IP, knockdown/overexpression, far-Western, in vitro kinase and reporter assays\",\n      \"pmids\": [\"14970219\", \"15542607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of IQGAP1 scaffolding to physiological ERK output unclear\", \"PAK1 feedback magnitude in vivo not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Expanded the ERK2 substrate landscape using chemical genetics, identifying the E3 ligase EDD and the nucleoporin Tpr as direct substrates.\",\n      \"evidence\": \"Engineered ERK2(Q103G) with bulky ATP analog, in vitro and in vivo phosphorylation validation\",\n      \"pmids\": [\"12594221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of EDD/Tpr phosphorylation not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked ERK2 to upstream activating receptors and to a downstream kinase, defining the SHP2→GAB1→ERK2 axis and capturing the ERK2–RSK1 precatalytic complex.\",\n      \"evidence\": \"Crystallography with MD simulation (RSK1); phosphatase/kinase assays and dominant-negative GAB1 epistasis (SHP2/GAB1)\",\n      \"pmids\": [\"25730857\", \"10593929\", \"14974085\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics of transition to fully catalytic RSK1 complex inferred from structure\", \"GAB1 axis studied largely via overexpression/mutants\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated that ERK2 regulatory complexes are conformationally dynamic, with resting ERK2:HePTP extended and the active complex compact in solution.\",\n      \"evidence\": \"SAXS with EROS ensemble refinement on purified complexes\",\n      \"pmids\": [\"21985012\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No orthogonal functional validation\", \"Single structural method\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined ERK2 control of regulated proteins via degradation and phase behavior, and its role in chromatin-based gene activation, showing ULK1/Shank3 degradation, CPEB4 monomerization, and PARP1-dependent recruitment to IEG promoters.\",\n      \"evidence\": \"In vitro kinase/ubiquitination and phase-separation assays, Co-IP, ChIP, knockout mice, LTP electrophysiology\",\n      \"pmids\": [\"27802129\", \"27121568\", \"30696942\", \"33213267\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Several pathways rest on single-lab Co-IP plus rescue\", \"Direct vs. indirect contributions in vivo not fully separated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established ERK2 as a metabolic and organelle regulator, phosphorylating PFAS to boost de novo purine synthesis and modulating mitochondrial dynamics through PACS-2/MAM control.\",\n      \"evidence\": \"In vitro kinase assay, 13C metabolic flux analysis, phosphomutant xenografts; diabetic mouse/HK-2 models with MAPK1 inhibition and PACS-2 rescue\",\n      \"pmids\": [\"32485148\", \"38169625\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PACS-2 regulation mechanism (direct vs. indirect) not fully defined\", \"ERK1 vs. ERK2 specificity for PACS-2 effect untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed kinase-independent and isoform-specific ERK2 functions, including bidirectional transcription-factor activity at gastric cancer promoters and mechanically activated ERK2 remodeling cytoskeletal junctions.\",\n      \"evidence\": \"ChIP-seq/RNA-seq with functional assays; Xenopus mechanical stimulation with phosphoproteomics and FGFR1 inhibition\",\n      \"pmids\": [\"37817112\", \"32187556\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinase-independent transcriptional role shown in a single cell line\", \"Direct DNA-binding mechanism not structurally defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected ERK2-specific activity to disease-relevant phenotypes, showing ERK2 drives EMT, invasion, and BRAF-inhibitor-resistant melanoma drug addiction distinct from ERK1.\",\n      \"evidence\": \"CRISPR knockout screens, isoform-specific rescue, 3D invasion assays, mouse models, patient tissue analysis\",\n      \"pmids\": [\"28976960\", \"22328529\", \"30728292\", \"24691442\", \"28689659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of ERK2 vs ERK1 functional divergence incompletely defined\", \"Some downstream pathways established by epistasis rather than direct substrate phosphorylation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ERK2 achieves substrate-specific outputs from a single conformationally dynamic active site—integrating docking, scaffolding, localization, and kinase-independent functions—remains incompletely defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking conformational state to substrate selection in cells\", \"Kinase-independent transcription-factor role mechanistically unresolved\", \"Determinants of ERK1 vs ERK2 isoform specificity unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 11, 12, 16, 17, 19, 20, 21, 32]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [3, 9, 17]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [36]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [36, 28]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 33]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 27]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [24, 34]},\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [28]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 29, 30]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [18, 24, 35]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [17, 23, 34]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [19, 28, 36]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [25, 26, 29]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [16, 30, 32]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MEK1\", \"MKP3/DUSP6\", \"RSK1\", \"IQGAP1\", \"MEKK1\", \"GAB1\", \"PAK1\", \"Par3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}